ACS Sensors Demonstrates Modular Biosensor Design with De Novo Protein Switch ‘LOCKR’ for Troponin I and HBV Antibody Detection

ACS Sensors USA

Overview

A study in ACS Sensors introduces a modular input-output biosensor design utilizing the de novo protein switch platform, LOCKR. This platform enables direct conversion of target binding events into specific signal outputs, coupling target recognition and signal generation through thermodynamic equilibrium. The research successfully demonstrated multiple readout formats, including a chromatic biosensor for cardiac troponin I and a ratiometric BRET biosensor for hepatitis B virus antibodies, addressing the critical challenge of reliably translating target binding into a detectable signal in protein-based biosensor design.

In Depth

Key Findings

A pioneering study published in ACS Sensors reports the design of modular input-output biosensors based on the de novo (newly designed) protein switch platform, LOCKR. This innovative approach possesses the capability to directly convert binding events into specific, detectable signal outputs, efficiently coupling the processes of target recognition and signal generation through thermodynamic equilibrium. This design resolves a fundamental challenge long faced by protein-based biosensors: reliably translating target binding into a consistent and reproducible signal. As proof-of-concept, multiple distinct readout formats were successfully developed, including a chromatic biosensor for cardiac troponin I and a ratiometric BRET (Bioluminescence Resonance Energy Transfer) biosensor for hepatitis B virus (HBV) antibodies.

Technical and Clinical Details

The LOCKR platform offers a significant advantage in its modularity, allowing flexible biosensor construction for a variety of target molecules. In this system, target binding induces a conformational change in the protein, which is then translated into a specific physical or chemical signal, such as color change, fluorescence, or luminescence. For instance, the chromatic biosensor for cardiac troponin I could trigger a visible color shift, potentially enabling visual interpretation without specialized equipment. The ratiometric BRET biosensor for HBV antibody detection, on the other hand, leverages energy transfer between two distinct fluorophores to provide high sensitivity and quantitative measurement capabilities. This design principle enhances the sensor’s specificity and signal-to-noise ratio, enabling highly accurate detection even in complex biological samples. While traditional protein sensors have faced challenges in stability and reproducibility, de novo designed proteins offer more robust structures and predictable behavior, advantageous in overcoming these issues.

Background and Industry Context

In diagnostic medicine and research, biosensors capable of sensitive and specific detection of particular biomarkers are indispensable. However, existing protein-based sensors have grappled with complexities in design, low stability, and unreliable signal transduction. De novo design approaches, like the LOCKR platform, aim to surmount these limitations, enabling the development of more robust and tunable biosensors. Cardiac troponin I is a critical biomarker for diagnosing heart attacks, and HBV antibodies are essential for hepatitis B diagnosis and screening. These demonstrations suggest that this technology holds significant potential for a wide range of clinical applications, from rapid diagnosis of acute conditions to infectious disease screening.

Strategic Significance and Outlook

This modular biosensor design represents a crucial step in the convergence of protein engineering and diagnostic technology. Future prospects involve further advancing the LOCKR platform to develop multiplexing sensors, integrate with wearable devices, and broaden applications to areas such as real-time drug monitoring and environmental pollutant detection. The stability and tunability of de novo designed proteins offer unprecedented opportunities in developing new diagnostic tools and research reagents, accelerating the realization of personalized medicine and rapid point-of-care testing (POCT).